Agios Pharma (AGIO): 'Aqvesme's opportunity in thalassemia reason enough to own the stock,' says analyst

March 12, 2026 9:27 AM

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating and {REMOVEPT} price target on Agios Pharma (NASDAQ: AGIO).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found